Human TNF Cytokine Neutralization with a VNAR from Heterodontus Francisci Shark: a Potential Therapeutic Use

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2012 Dec 11

PMID 23221782

Citations 23

Authors

Tanya Camacho-Villegas

Teresa Mata-Gonzalez

Jorge Paniagua-Solis

Edna Sanchez

Alexei Licea

Affiliations

Soon will be listed here.

Abstract

The therapeutic use of single domain antibodies (sdAbs) is a promising new approach because these small antibodies maintain antigen recognition and neutralization capacity, have thermal and chemical stability and have good solubility. In this study, using phage display technology, we isolated a variable domain of a IgNAR (vNAR) from a Heterodontus francisci shark immunized against the recombinant human cytokine TNFα (rhTNFα). One clone T43, which expresses the vNAR protein in the periplasmic space, was isolated from the fourth round of panning. T43 had the capacity to recognize rhTNF and neutralize it in vitro, indicating that T43 has potential as a therapeutic that can be used for diseases in which this pro-inflammatory cytokine needs to be controlled.

Citing Articles

Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray ( spp.) as a Drug Carrier in Glioblastoma Cancer Cells.

Manzanares-Guzman A, Alfonseca-Ladron de Guevara A, Reza-Escobar E, Burciaga-Flores M, Canales-Aguirre A, Esquivel-Solis H Int J Mol Sci. 2025; 26(3).

PMID: 39940647 PMC: 11817625. DOI: 10.3390/ijms26030876.

vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.

Manzanares-Guzman A, Lugo-Fabres P, Camacho-Villegas T Antibodies (Basel). 2024; 13(1).

PMID: 38534215 PMC: 10967338. DOI: 10.3390/antib13010025.

Osteoarthritis versus psoriasis arthritis: Physiopathology, cellular signaling, and therapeutic strategies.

Juma S, Liao J, Huang Y, Vlashi R, Wang Q, Wu B Genes Dis. 2024; 11(3):100986.

PMID: 38292181 PMC: 10825447. DOI: 10.1016/j.gendis.2023.04.021.

Chimeric Peptides from and with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies).

Duenas S, Escalante T, Gasperin-Bulbarela J, Bernaldez-Sarabia J, Cervantes-Luevano K, Jimenez S Toxins (Basel). 2023; 15(4).

PMID: 37104207 PMC: 10141372. DOI: 10.3390/toxins15040269.

First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment.

Burciaga-Flores M, Marquez-Aguirre A, Duenas S, Gasperin-Bulbarela J, Licea-Navarro A, Camacho-Villegas T Sci Rep. 2023; 13(1):3596.

PMID: 36869086 PMC: 9982792. DOI: 10.1038/s41598-023-30623-x.

References

MINSKY A, Summers R, Knowles J . Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci U S A. 1986; 83(12):4180-4. PMC: 323695. DOI: 10.1073/pnas.83.12.4180. View

Van Bockstaele F, Holz J, Revets H . The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs. 2009; 10(11):1212-24. View

Roux K, Greenberg A, Greene L, Strelets L, Avila D, McKinney E . Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci U S A. 1998; 95(20):11804-9. PMC: 21721. DOI: 10.1073/pnas.95.20.11804. View

Fennell B, Darmanin-Sheehan A, Hufton S, Calabro V, Wu L, Muller M . Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms. J Mol Biol. 2010; 400(2):155-70. DOI: 10.1016/j.jmb.2010.04.061. View

Simmons D, Streltsov V, Dolezal O, Hudson P, Coley A, Foley M . Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures. Proteins. 2007; 71(1):119-30. DOI: 10.1002/prot.21663. View

Thalayasingam N, Isaacs J . Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011; 25(4):549-67. DOI: 10.1016/j.berh.2011.10.004. View

Nuttall S, Krishnan U, Hattarki M, De Gori R, Irving R, Hudson P . Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol. 2001; 38(4):313-26. DOI: 10.1016/s0161-5890(01)00057-8. View

Greenberg A, Avila D, Hughes M, Hughes A, McKinney E, Flajnik M . A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 1995; 374(6518):168-73. DOI: 10.1038/374168a0. View

Hudson P, Souriau C . Engineered antibodies. Nat Med. 2003; 9(1):129-34. DOI: 10.1038/nm0103-129. View

10.

Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M . Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009; 198(3):157-74. PMC: 2714450. DOI: 10.1007/s00430-009-0116-7. View

11.

Kim S, Park Y, Hong H . Antibody engineering for the development of therapeutic antibodies. Mol Cells. 2005; 20(1):17-29. View

12.

Gay R, Clarke A, Elgundi Z, Domagala T, Simpson R, Le N . Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs. 2010; 2(6):625-38. PMC: 3011217. DOI: 10.4161/mabs.2.6.13493. View

13.

Sivashanmugam A, Murray V, Cui C, Zhang Y, Wang J, Li Q . Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Sci. 2009; 18(5):936-48. PMC: 2771296. DOI: 10.1002/pro.102. View

14.

Juarez K, Dubberke G, Lugo P, Koch-Nolte F, Buck F, Haag F . Monoclonal antibodies for the identification and purification of vNAR domains and IgNAR immunoglobulins from the horn shark Heterodontus francisci. Hybridoma (Larchmt). 2011; 30(4):323-9. DOI: 10.1089/hyb.2011.0010. View

15.

Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P . Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006; 54(6):1856-66. DOI: 10.1002/art.21827. View

16.

Nuttall S, Krishnan U, Doughty L, Nathanielsz A, Ally N, Pike R . A naturally occurring NAR variable domain binds the Kgp protease from Porphyromonas gingivalis. FEBS Lett. 2002; 516(1-3):80-6. DOI: 10.1016/s0014-5793(02)02506-1. View

17.

Dooley H, Flajnik M, Porter A . Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol. 2003; 40(1):25-33. DOI: 10.1016/s0161-5890(03)00084-1. View

18.

Stanfield R, Dooley H, Flajnik M, Wilson I . Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science. 2004; 305(5691):1770-3. DOI: 10.1126/science.1101148. View

19.

Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauferon F, Ternant D . Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011; 13(3):R105. PMC: 3218920. DOI: 10.1186/ar3386. View